Literature DB >> 23013249

Semiparametric Bayesian survival analysis using models with log-linear median.

Jianchang Lin1, Debajyoti Sinha, Stuart Lipsitz, Adriano Polpo.   

Abstract

We present a novel semiparametric survival model with a log-linear median regression function. As a useful alternative to existing semiparametric models, our large model class has many important practical advantages, including interpretation of the regression parameters via the median and the ability to address heteroscedasticity. We demonstrate that our modeling technique facilitates the ease of prior elicitation and computation for both parametric and semiparametric Bayesian analysis of survival data. We illustrate the advantages of our modeling, as well as model diagnostics, via a reanalysis of a small-cell lung cancer study. Results of our simulation study provide further support for our model in practice.
© 2012, The International Biometric Society No claim to original US government works.

Entities:  

Mesh:

Year:  2012        PMID: 23013249      PMCID: PMC5557061          DOI: 10.1111/j.1541-0420.2012.01782.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  5 in total

1.  A Bayesian semiparametric accelerated failure time model.

Authors:  S Walker; B K Mallick
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

2.  Median regression with censored cost data.

Authors:  Heejung Bang; Anastasios A Tsiatis
Journal:  Biometrics       Date:  2002-09       Impact factor: 2.571

3.  Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada.

Authors:  W K Evans; R Feld; N Murray; A Willan; P Coy; D Osoba; F A Shepherd; D A Clark; M Levitt; A MacDonald
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

Review 4.  Clinical trials of cyclophosphamide, etoposide, and vincristine in the treatment of small-cell lung cancer.

Authors:  R L Comis
Journal:  Semin Oncol       Date:  1986-09       Impact factor: 4.929

5.  Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group.

Authors:  J R Jett; L Everson; T M Therneau; J E Krook; R J Dalton; R F Marschke; M H Veeder; S F Brunk; J A Mailliard; D I Twito
Journal:  J Clin Oncol       Date:  1990-01       Impact factor: 44.544

  5 in total
  1 in total

1.  Bayesian partial linear model for skewed longitudinal data.

Authors:  Yuanyuan Tang; Debajyoti Sinha; Debdeep Pati; Stuart Lipsitz; Steven Lipshultz
Journal:  Biostatistics       Date:  2015-03-19       Impact factor: 5.899

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.